

# At FDA Urging, Pfizer and Moderna to Include Thousands More Children in Clinical Trials

By <u>Children's Health Defense</u> Global Research, July 28, 2021 <u>Children's Health Defense</u> 27 July 2021 Region: <u>USA</u> Theme: <u>Science and Medicine</u>

All Global Research articles can be read in 51 languages by activating the "Translate Website" drop down menu on the top banner of our home page (Desktop version).

Visit and follow us on Instagram at @crg\_globalresearch.

\*\*\*

Citing concerns about the risk of heart inflammation associated with the vaccines, the U.S. Food and Drug Administration asked Pfizer and Moderna to expand the number of children in their clinical trials.

Pfizer and Moderna will increase the number of children in their COVID vaccine clinical trials prior to seeking <u>Emergency Use Authorization</u> (EUA), after the U.S. Food and Drug Administration (FDA) told the vaccine makers the size and scope of their pediatric studies, as initially envisioned, were inadequate to detect rare side effects.

The rare side effects cited by the FDA include <u>myocarditis</u>, an inflammation of the heart muscle, and <u>pericarditis</u>, inflammation of the lining around the heart, multiple people familiar with the trials told <u>The New York Times</u>.

<u>Moderna's</u> shot is authorized for emergency use in people 18 and up, and <u>Pfizer's</u> vaccine is authorized for children as young as 12. No COVID vaccines have yet received EUA approval for children younger than 12.

Expanding the pediatric trials means thousands more children as young as 6 months old may soon be recruited and enrolled in COVID vaccine trials.

According to the Times, the FDA asked the companies to include 3,000 children in the 5- to 11-year-old group, the group for whom results were expected first.

One person, granted anonymity by the Times to speak freely, described that figure as double the original number of study participants.

Moderna researchers had intended to test the vaccine in about 7,000 children, with some as young as 6 months, <u>according to ABC News</u>, but the company told the news outlet today in an email they never decided on how many kids would be added to the trial.

Pfizer began testing its vaccine in children ages 5 to 11 on June 8, with those younger than 5 being included as of June 21. The study will involve up to 4,500 subjects from the U.S.,

Finland, Poland and Spain, <u>according to the Wall Street Journal</u>, which also reported the company declined to say whether the recent request from the FDA will change the timing of any authorization submissions.

Last month, Pfizer and Moderna <u>said</u> their vaccines for children 5 through 11 could be ready as early as September. Pfizer, which is on a faster timetable than Moderna, may be able to meet the FDA's expectations on a bigger trial size and still file a request for expanded EUA by the end of September, the Times reported.

A federal official, who <u>spoke to the Washington Post</u> on the condition of anonymity because they were not authorized to speak publicly, predicted authorization of a COVID vaccine for children 5 through 11 might come by late October or early November.

The government is not expecting it will be a big problem to enroll more children because so many parents are eager to get their children vaccinated, the official said.

#### Heart inflammation in teens raises red flag

Moderna spokesman Ray Jordan told the Post the goal is "to enroll a larger safety database which increases the likelihood of detecting rarer events."

#### According The Washington Post:

"The FDA wants to be particularly careful about the possibility of children developing myocarditis, or heart inflammation, after receiving a coronavirus vaccine. Adolescents who receive the vaccines are more likely to develop myocarditis than adults — though the risk remains small — and officials want to increase the chances that the trials will indicate whether there is increased incidence of heart inflammation in children."

The Centers for Disease Control and Prevention in June <u>acknowledged</u> 1,200 cases of heart inflammation in 16- to 24-year-olds, and said <u>mRNA COVID vaccines</u> should carry a warning statement. The FDA followed by <u>adding</u> the warning.

According to the <u>latest data</u> available, the CDC's <u>Vaccine Adverse Event Reporting System</u> has received <u>383 reports</u> of myocarditis and pericarditis in vaccine recipients between the ages of 12 and 17 years old, with <u>379 cases</u> attributed to Pfizer's vaccine.

For all age groups during the same period, <u>1,848 cases</u> of myocarditis and pericarditis were reported to VAERS, with <u>1,176 cases</u> attributed to Pfizer, <u>606 cases</u> to Moderna and <u>62 cases</u> to J&J's COVID vaccine.

The data reflects reports received between Dec. 14, 2020 and July 16, 2021. The FDA first authorized Pfizer's vaccine for 12- to 15-year-olds in May of this year.

Despite the known cases and the FDA warning, the CDC said the benefits of the vaccine outweigh the risk.

## Doctors weigh in on ill-advised rush to vaccinate kids

The authors of an <u>op-ed</u> published earlier this month in The BMJ argued that even if one assumes the vaccine provides protection against severe COVID, given its "very low

incidence in children," an extremely high number would need to be vaccinated in order to prevent one severe case.

Meanwhile, a large number of children with very low risk for severe disease would be exposed to vaccine risks, known and unknown, they said.

They wrote:

"In the clinical trial underlying the authorization of <u>Pfizer-BioNTech</u>'s mRNA vaccine in children aged 12 to 15, of the close to 1000 children who received placebo, 16 tested positive for COVID-19, compared to none in the fully vaccinated group.

"Given this low incidence, the fact that COVID-19 is generally asymptomatic or mild in children, and the <u>high rate of adverse events</u> in those vaccinated (e.g. in Pfizer's trial of 12-15 year olds, 3 in 4 kids had fatigue and headaches, around half had chills and muscle pain, and around 1 in 4 to 5 had a fever and joint pain), a comparison of quality-adjusted life-years in the trial would very much favor the placebo group."

Doctors for COVID Ethics, an EU-based international alliance of <u>hundreds</u> of concerned doctors and scientists, <u>said COVID vaccines</u> are not only "unnecessary and ineffective," but also "dangerous for children and adolescents."

Three of the group's <u>founding signatories</u> — **Dr. Michael Palmer** (Canada), **Dr. Sucharit Bhakdi**, (Germany) and **Stefan Hockertz, Ph.D.** (Germany) — assembled in one document powerful <u>expert evidence</u> that highlights the Pfizer vaccine's "catastrophically bad" safety profile in both adults and adolescents.

In an <u>open letter</u> to the EU's Medicines and Healthcare Products Regulatory Agency, more than 40 doctors, medics and scientists in the UK said children are more vulnerable to the potential long-term effects of COVID vaccines.

In an open letter to the Medicines and Healthcare Products Regulatory Agency, more than 40 doctors, medics and scientists in the UK say children are more vulnerable to the potential long-term effects of COVID vaccines. <u>#TheDefender https://t.co/kkglp6jFsv</u>

- Robert F. Kennedy Jr (@RobertKennedyJr) June 1, 2021

Vaccinating kids for COVID is "irresponsible, unethical and unnecessary," they said.

The letter warned against vaccinating people under 18 because evidence shows the virus poses almost <u>no risk</u> to healthy children. The <u>risk of death</u> from COVID in healthy children is 1 in 1.25 million, the authors wrote.

COVID vaccines, however, are linked to strokes due to cerebral venous thromboses in people under 40 — a finding that "led to the suspension of the <u>Oxford-AstraZeneca</u> children's trial," the authors said.

The doctors wrote:

"Children have a lifetime ahead of them, and their immunological and neurological

systems are still in development, making them potentially more vulnerable to <u>adverse</u> <u>effects</u> than adults."

According to the <u>latest available data</u> for 12- to 17-year-olds, between Dec. 14, 2020 and July 16, 2021, VAERS received a total of <u>14,494</u> reports of adverse events related to COVID vaccines, including <u>871 rated as serious</u> and <u>17 deaths</u>.

\*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg\_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is from Children's Health Defense

The original source of this article is <u>Children's Health Defense</u> Copyright © <u>Children's Health Defense</u>, <u>Children's Health Defense</u>, 2021

## **Comment on Global Research Articles on our Facebook page**

## **Become a Member of Global Research**

Articles by: Children's Health Defense

**Disclaimer:** The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: <a href="mailto:publications@globalresearch.ca">publications@globalresearch.ca</a>

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca